Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by IrishCanuckon Jan 25, 2021 11:07pm
255 Views
Post# 32383818

New vaccines will remove more uncertainty

New vaccines will remove more uncertaintyJohnson & Johnson vaccine can be stored in the fridge, infrastructure is way easier, 100 million doses available by April, a single shot is needed, it just comes down to its effectiveness now. We need three more months out of the way for the whole world to sort things out.

Heads up, I'm not bashing here: The first half of 2021 is sort of a write off at this point now I guess for Antibe. We're going to be $4 until May unless there is another dilution which is more likely with Phase 3's delay. Only a partnership will serve as a catalyst and we know that is going to take months to sort out. The 6-week AME study is great, it can only help our negotiations as it's meant to derisk Phase 3, but doesn't outweigh the delay.

Do you have a month you're predicting an uptick? I doubt the IND application would be a catalyst. I hope my other stocks make money until May before I go all in here still at $4 so I get more before going all in. When we're approved to begin Phase 3 I think it will be the catalyst, hence May. I could easily see myself jump the gun and do it in April too. 

https://www.marketwatch.com/story/fauci-says-johnson-johnson-covid-19-vaccine-may-get-approval-in-two-weeks-11611443596
<< Previous
Bullboard Posts
Next >>